Testosterone in Female Hypoactive Sexual Desire Disorder - Article
Clinical Trial: Testosterone in Female Hypoactive Sexual Desire Disorder
This study is currently recruiting patients.
Verified by Beersheva Mental Health Center August 2005
|Hypoactive Sexual Desire Disorder || Drug: testosterone gel (Androgel) ||Phase III |
MedlinePlus related topics: Female Sexual Dysfunction
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment
Official Title: Transdermal Testosterone Gel Prn Application for Hypoactive Sexual Desire Disorder in Women: A Controlled Study
Expected Total Enrollment: 20
Study start: April 2005; Expected completion: April 2005
The role of androgens in addition to estrogens in female sexual health has been known for several decades [Davis and Tran 2001]. Recently methods of delivering testosterone other than by injection have made the use of androgens in treatment more available. Testosterone gel is absorbed well [Wang, et al. 2000] and has been shown to be effective in the treatment of hypogonadal men. Doses of 100 mg gel rubbed into skin increased testosterone levels to 30-40 nmoles/L within 8-20 hours. Levels returned to baseline in this study within 1-2 days after cessation of chronic treatment although return to baseline after a single application was not studied.
A recent study [Shifren, et al. 2000] has shown that transdermal continuous patch testosterone dose 150g or 300g vs. placebo daily during the 12 week study improved sexual health including desire, arousal, and orgasm frequency in women with surgically induced menopause after oopherectomy. Blood levels reached 3.0nmoles/L (5x baseline). Shrifren et al  found no significant side effects with transdermal sustained testosterone treatment. Another study [Goldstat, et al. 2003] looked at transdermal testosterone given in gel, 10mg a day given for 12 weeks in a double-blind design for 31 pre-menopausal women with a mean age of 40 years. The women entered the study presenting with low sexual desire. Testosterone treatment resulted in a significant improvement in psychological general well being and sexual self rating scale. No adverse effects were reported. Blood levels of testosterone increase about 2.5 times baseline to 2.6nmoles/L.
Despite the absence of side effects reported in the small studies for relatively short periods of time done up till now in women with testosterone treatment, in the treatment of a long term disorder such as diminished sexual desire it is reasonable to be concerned with androgenizing side effects. Therefore, it would be extremely useful if testosterone could be given on a prn (as needed) basis before sexual intercourse. Recently Tuiten et al  studied normal volunteer women with vaginal flow measures using photoplethysmography in addition to questionnaire data on sexual arousal after exposure to erotic movies with pre treatment of sublingual testosterone vs. placebo in a single dose sublingually of 0.5mg. Testosterone significantly enhanced vaginal blood flow response to the erotic movies and also the subjective sexual interest, desire and arousal to the movies. The psychophysiological effect was maximal 4 hours after the sublingual testosterone. Blood levels of 25nmol/L testosterone, 10 times baseline, were maximal 10 minutes after sublingual delivery and returned to baseline within 90 minutes.
This study suggested that it may be possible to give transdermal testosterone 4-8 hours before intercourse in couples where the female partner suffers from low sexual interest or desire and /or difficulties in arousal, but where the couple is able to plan intercourse several hours in advance, which is possible in many couples, based on our clinical experience. In such couples androgen could be given on a prn basis and the possibility of side effects with long term use greatly reduced. We therefore propose such a study.
Methods The study will be done as a double-blind randomized crossover study. Women entering the study will be pre-menopausal ages 21-40 with a diagnosis of hypo-active sexual disorder by an experienced sexologist diplomate of the Israel Society for Sexual Therapy. Patients will be accepted for study only if they can plan intercourse with their partner. Patients unable to do so will be offered 3 sessions of counseling about sexual communication and those still unable to plan intercourse after those 3 sessions will be excluded from the study. Patients accepted for the study after written informed consent will be given 8 packets of Testosteron Gel (Androgel) 50mg and shown how to spread the gel on the skin of the lower abdomen or upper shoulders. They will be told that they can use the gel up to twice weekly for one month. Patients will be instructed to spread the gel 4-8 hours before planned intercourse. The patients will be instructed to shower to remove any remaining gel after intercourse. After each intercourse they will fill out the Arizona Sexual Experiences Scale (ASEX)- Female [McGahuey, et al. 2000]. At baseline and at the end of the month they will be interviewed and rated for the month as a whole using the Sexual Function Questionnaire (SFQ-V1) [Quirk, et al. 2002]. They will then be given a package of 8 placebo gels with the same instruction and invited back after a month for another rating. Half of the women will be given placebo and then switched over to active androgen.
We request permission to advertise on the internet and/or in newspapers for symptomatic volunteers for the study.
Possible (but improbable due to the low doses and the prn use) side effects include: Increase in total cholesterol, high density lipoprotein cholesterol, low density lipoprotein cholesterol, triglycerides, fasting glucose and insulin; changes in blood counts and changes in liver function tests (serum aspartate aminotransferase, serum glutamyltransferase, serum albumin); hirsutism and acne, increase in facial hair or loss of hair; diarrhea, nipple and breast enlargement or breast pains; headache; elevation of blood pressure, changes in mood or aggressiveness. Slight local skin irritation or dryness of skin. However, as stated before, these side effects are unlikely using prn treatment.
Dose: The recent study of Shifren et al  used continuous transdermal patch and reached blood levels of 3.0nmoles/L (5x baseline) in post-menopausal women, with no side effects over 12 weeks. Goldstat et al  looked at transdermal gel 10mg, which is applied daily but washes off as the day wears on, for 12 weeks with no side effects in pre-menopausal women. They reached blood levels of 2.6nmoles/L (2.5x baseline). Tuiten et al  used sublingual one time dose of 0.5mg, reaching a peak blood level of 25nmoles/L (10x baseline) at 10 minutes which returned to baseline within 90 minutes. We propose to minimize side effects and maximize benefit by single application use of 50mg testosterone in transdermal gel to be used only up to twice a week. Blood levels from this dose from Wang et al  should be about 20nmoles/L. Since patients are instructed to shower after intercourse, these blood levels should exist for only 4-8 hours twice a week. Based on Tuiten et al  a short pulse of testosterone up to these levels is necessary to achieve psychophysiological effects, and thus we request permission to use a dose of 50mg Androgel which would be too high if used daily chronically in women.
pre-menopausal females, hypoactive sexual disorder, age 21-40, able to plan intercourse with partner -
Location and Contact Information
RH Belmaker, MD 972-8-6401602 email@example.com
Beersheva Mental Health Center, Beersheva, Israel; Recruiting
RH Belmaker, MD 972-8-6401602 firstname.lastname@example.org
Bella Chudakov, MD, Principal Investigator
RH Belmaker, MD, Study Director, Beersheva Mental Health Center
Last Updated: August 31, 2005
Record first received: August 31, 2005
ClinicalTrials.gov Identifier: NCT00140153
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration
ClinicalTrials.gov processed this record on 2005-09-06